Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition - Wikidata - thesis-toulmin - TriplyDB

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition

http://www.wikidata.org/entity/Q34015968

about

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists Basal insulin combined incretin mimetic therapy with glucagon-like protein 1 receptor agonists as an upcoming option in the treatment of type 2 diabetes: a practical guide to decision making Effects of GLP-1 on appetite and weight Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists.Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes Liraglutide attenuates high glucose-induced abnormal cell migration, proliferation, and apoptosis of vascular smooth muscle cells by activating the GLP-1 receptor, and inhibiting ERK1/2 and PI3K/Akt signaling pathways.Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.Exenatide exerts a potent antiinflammatory effect.Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis.Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.Potential use of exenatide for the treatment of obesity.GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Evolution of exenatide as a diabetes therapeutic.Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes Effects of Exendin-4 on human adipose tissue inflammation and ECM remodelling.Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies.Is the GLP-1 system a viable therapeutic target for weight reduction?Clinical implications of exenatide as a twice-daily or once-weekly therapy for type 2 diabetes.The effect of glucagon-like peptide 1 on cardiovascular risk.Potential cardiovascular effects of incretin-based therapies.Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies.GLP-1 receptor agonists: effects on cardiovascular risk reduction.The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.Incretin-related drug therapy in heart failure.Implications of incretin-based therapies on cardiovascular disease.Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies.Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.Diabetes in Cushing Disease.Liraglutide treatment in a patient with HIV and uncontrolled insulin-treated type 2 diabetes.Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans.Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.Adiponectin, Leptin, and Leptin Receptor in Obese Patients with Type 2 Diabetes Treated with Insulin Detemir.

P2860

Q26749495-DBCD1AFF-D38F-4C79-97B3-C61DDCA7E475 Q26992979-1BA6BDEA-EEB2-4292-95BB-484DD6FB856B Q27011627-3544DC8E-D146-4300-B1A3-7BE015FBE9C2 Q28741419-0DDCE125-69AB-4C28-9D82-4E84B8F87293 Q34405101-CC8B27C6-F2BA-4B71-8E7E-58E78524B687 Q34510307-E6E606A2-DACA-44F9-ABE5-18948754CF88 Q34994502-3DE171F7-AEE9-4C72-B679-6792FDC979FE Q35082511-2787FB85-0126-467B-AB12-8BB40E833021 Q35179964-27B73EF1-3A00-43DD-9970-947F62532F3C Q35223375-91BEE426-D1BD-4962-9170-40E513825263 Q35654205-73847A42-EBF2-46A6-BFD8-B9313DA4E45B Q35784692-8A93214F-9A24-4C0D-9283-682688B75F56 Q35936644-34902196-BA8F-4F34-A43F-5F90FB5C08A1 Q36023385-5F2CA594-AA14-47FC-926F-6DB69881B65B Q36209444-1DAB05A1-A4AD-488F-B78D-6C9182725C5A Q36391466-C7683385-C01E-4903-94D5-BEB8769C765A Q36406821-4D5BB5E3-A27C-4583-9D95-E58B75950245 Q36877205-D5FE8338-5FED-45A8-8632-82A8641C5076 Q37561260-C255E314-3598-405C-816C-6474175817AB Q37575885-8DA600D5-9128-4CD5-B49B-C33720648CF7 Q37828337-4B47535A-D427-4708-9C62-A566D55DCE81 Q37845218-F2B55F96-05F9-4580-8A0D-D84993D34E69 Q37929511-00C8D212-794D-456A-AAAE-18A2161ADD29 Q37980019-C48D383F-6831-4911-B459-366512E54591 Q37990619-98CE3FE8-CAB4-421C-8E6B-E6C15DC7B6B0 Q37995760-E78A1E69-E98A-4925-BD48-95242C642685 Q38065321-167CAB63-8BCF-4F60-A677-CB2DB50BCC61 Q38071847-CD898E43-B3E9-4D69-9CFB-673E8BA80FD3 Q38122396-17BC8DCF-929D-4C35-928B-4D93C4CE65BD Q38145277-7EAD1994-23DC-4701-BEBA-E30DE102BAEF Q38260853-BDEA0C18-5E1D-4CB0-BC8F-3496C3F4BAF1 Q38264374-9DE39C4D-FEFF-4136-A4F9-D281D13D0F31 Q38460480-95782113-0933-4BD1-B7DB-63DBAF25E297 Q38702260-F2CE03CB-6FB1-45B8-B714-53D3EB4D4D01 Q38815279-F1A028A1-96FA-4D15-97FE-CC9DCE9911B9 Q39212408-A07029AA-947A-4862-9061-5AD68733F69B Q42539644-937B45C7-4CB3-4338-A752-329ED99A24C6 Q42576497-A27B0E89-ED61-44FA-B7BB-26C5EF27408F Q44080580-A3953095-C4C0-459C-85BC-1FEE6A29E857 Q47745734-4BAD0560-2BD0-4084-B0F2-B1CEEFE2FDC5

P2860

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition

http://www.wikidata.org/entity/Q34015968

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Exenatide affects circulating ...... of changes in body composition

@ast

Exenatide affects circulating ...... of changes in body composition

@en

Exenatide affects circulating ...... of changes in body composition

@nl

type

label

Exenatide affects circulating ...... of changes in body composition

@ast

Exenatide affects circulating ...... of changes in body composition

@en

Exenatide affects circulating ...... of changes in body composition

@nl

prefLabel

Exenatide affects circulating ...... of changes in body composition

@ast

Exenatide affects circulating ...... of changes in body composition

@en

Exenatide affects circulating ...... of changes in body composition

@nl

P1433

Q34015968-6E77F584-8599-411C-8A6C-A462C849E20B

P1476

Q34015968-15F796D1-3F15-4468-9F3B-286E5BA55C7C

P2093

Q34015968-1E436C8D-CC40-48DD-AE4C-83B9E3385FF1

Q34015968-31F9D975-30EE-4FBE-82A2-332A8E74E097

Q34015968-3EE8C6A6-6A2E-45A0-A471-22F3771D89F5

Q34015968-533F089E-B4B7-43DE-B720-0A989109DC0F

Q34015968-A55DE29A-EE8F-4227-BD87-8DB694CAB708

Q34015968-E2CBB403-F411-4891-BA8E-9AA563D7B7DF

Q34015968-FA5AD863-BFE4-4954-B6FB-28A87358D3B2

P2860

Q34015968-0A61DBFA-4863-4D92-B7D5-4B9DE516422D

Q34015968-1804C083-2C26-40FB-B764-1D4A5453EAEC

Q34015968-3D8C43EE-89F3-400E-9AC2-63ABBC0922D4

Q34015968-4A81BBD8-7777-4CF5-9F1E-7D5F6F907502

Q34015968-5764C5BE-3565-466F-8BBD-978F2BB776B7

Q34015968-8FF3BF80-8771-4F0D-B639-79CF27B2282F

Q34015968-A6930911-F08A-4849-8833-10CFD3C91AAC

Q34015968-B5956318-B412-444D-82C5-8AD19493F248

Q34015968-B5C986A1-D897-4FCE-8E8D-A71802631743

Q34015968-C154F86C-3BF6-4D39-B30C-883B2981B7FD

P304

Q34015968-E9371D42-CFAE-47AC-90D6-377173A32382

P31

Q34015968-C68584F2-88A7-427B-A698-C50EE5663AC9

P356

Q34015968-176D541D-9994-4E9F-B8B7-1B1F4C6AB572

P407

Q34015968-F43D7C35-1A73-410B-A4E2-B4B31B319CB4

P433

Q34015968-9ADA6AF3-2555-422C-B05B-609C10F115F8

P478

Q34015968-400E103D-21A8-4D8D-B8A1-CEF76E00AEEB

P50

Q34015968-235FBCA4-6146-47DE-B050-8161EDD601C3

Q34015968-4C3C8262-D62E-456B-895D-18071ED22C72

P577

Q34015968-39D1BCDF-16A9-4464-9053-BB29D4888690

P5875

Q34015968-3ED7E798-772E-48D4-B844-C74908F073B6

P698

Q34015968-A3DAF611-11EF-491F-8103-C4C0687C00AA

P921

Q34015968-923D5DC3-4B66-404D-90B2-810E06465B16

Q34015968-F3DB526F-FD3F-4A90-A30A-01039A847F13

P932

Q34015968-9AD03147-6440-4A13-82A1-D8C69CB7A8FD

P356

P1433

P1476

Exenatide affects circulating ...... of changes in body composition

@en

P2093

Anja Cornér

http://www.w3.org/2001/XMLSchema#string

Bjorn Eliasson

http://www.w3.org/2001/XMLSchema#string

Marja-Riitta Taskinen

http://www.w3.org/2001/XMLSchema#string

Mathijs C Bunck

http://www.w3.org/2001/XMLSchema#string

Michaela Diamant

http://www.w3.org/2001/XMLSchema#string

Rimma M Shaginian

http://www.w3.org/2001/XMLSchema#string

Ulf Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Incretin mimetics as a novel therapeutic option for hepatic steatosis

The role of incretins in glucose homeostasis and diabetes treatment.

Role of body fat distribution and the metabolic complications of obesity.

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression.

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.

P304

1734-1737

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2337/DC09-2361

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Hannele Yki-Järvinen

Robert J. Heine

P577

2010-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43348371

http://www.w3.org/2001/XMLSchema#string

P698

20424219

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

2909051

http://www.w3.org/2001/XMLSchema#string